Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 95

1.

[Multirisk approach of the type 2 diabetic patient: controversies surrounding target values after the ACCORD trial].

Scheen AJ, Paquot N.

Rev Med Suisse. 2010 Sep 1;6(260):1582-7. French.

PMID:
20853712
[PubMed - indexed for MEDLINE]
2.

"If it ain't broke, don't fix it": a commentary on the positive-negative results of the ACCORD Lipid study.

Tenenbaum A, Fisman EZ.

Cardiovasc Diabetol. 2010 Jun 15;9:24. doi: 10.1186/1475-2840-9-24.

PMID:
20550659
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Pharmacologic prevention of microvascular and macrovascular complications in diabetes mellitus: implications of the results of recent clinical trials in type 2 diabetes.

Tandon N, Ali MK, Narayan KM.

Am J Cardiovasc Drugs. 2012 Feb 1;12(1):7-22. doi: 10.2165/11594650-000000000-00000. Review.

PMID:
22217193
[PubMed - indexed for MEDLINE]
4.

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.

Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kesäniemi YA, Sullivan D, Hunt D, Colman P, d'Emden M, Whiting M, Ehnholm C, Laakso M; FIELD study investigators.

Lancet. 2005 Nov 26;366(9500):1849-61. Erratum in: Lancet. 2006 Oct 21;368(9545):1415. Lancet. 2006 Oct 21;368(9545):1420.

PMID:
16310551
[PubMed - indexed for MEDLINE]
5.

Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods.

ACCORD Study Group, Buse JB, Bigger JT, Byington RP, Cooper LS, Cushman WC, Friedewald WT, Genuth S, Gerstein HC, Ginsberg HN, Goff DC Jr, Grimm RH Jr, Margolis KL, Probstfield JL, Simons-Morton DG, Sullivan MD.

Am J Cardiol. 2007 Jun 18;99(12A):21i-33i. Epub 2007 Apr 16.

PMID:
17599422
[PubMed - indexed for MEDLINE]
6.

[Clinical study of the month. Accord-lipid and accord-eye: towards a new positioning of fenofibrate in the management of type 2 diabetes].

Scheen AJ, Van Gaal LF.

Rev Med Liege. 2010 Sep;65(9):533-9. French.

PMID:
21086587
[PubMed - indexed for MEDLINE]
7.
8.

Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM). Results of the feasibility trial. Veterans Affairs Cooperative Study in Type II Diabetes.

Abraira C, Colwell JA, Nuttall FQ, Sawin CT, Nagel NJ, Comstock JP, Emanuele NV, Levin SR, Henderson W, Lee HS.

Diabetes Care. 1995 Aug;18(8):1113-23.

PMID:
7587846
[PubMed - indexed for MEDLINE]
9.

[Pharmacological therapy of obesity].

Pagotto U, Vanuzzo D, Vicennati V, Pasquali R.

G Ital Cardiol (Rome). 2008 Apr;9(4 Suppl 1):83S-93S. Italian.

PMID:
18773755
[PubMed - indexed for MEDLINE]
10.

[New treatment strategies for type-2 diabetes?].

Halimi S.

Presse Med. 2005 Oct 22;34(18):1287-92. Review. French.

PMID:
16269991
[PubMed - indexed for MEDLINE]
11.

Improvement of glycaemic control in type 2 diabetes: favourable changes in blood pressure, total cholesterol and triglycerides, but not in HDL cholesterol, fibrinogen, Von Willebrand factor and (pro)insulin.

Becker A, van der Does FE, van Hinsbergh VW, Heine RJ, Bouter LM, Stehouwer CD.

Neth J Med. 2003 Apr;61(4):129-36.

PMID:
12852722
[PubMed - indexed for MEDLINE]
Free Article
12.

The effect of interventions to prevent cardiovascular disease in patients with type 2 diabetes mellitus.

Huang ES, Meigs JB, Singer DE.

Am J Med. 2001 Dec 1;111(8):633-42.

PMID:
11755507
[PubMed - indexed for MEDLINE]
13.

Lipid-lowering therapy in patients with type 2 diabetes: the case for early intervention.

Steinmetz A.

Diabetes Metab Res Rev. 2008 May-Jun;24(4):286-93. doi: 10.1002/dmrr.806. Review.

PMID:
18273835
[PubMed - indexed for MEDLINE]
14.

Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.

Nesto RW.

Am J Cardiovasc Drugs. 2005;5(6):379-87. Review.

PMID:
16259526
[PubMed - indexed for MEDLINE]
15.

Fenofibrate therapy and cardiovascular protection in diabetes: recommendations after FIELD.

Vergès B.

Curr Opin Lipidol. 2006 Dec;17(6):653-8. Review.

PMID:
17095910
[PubMed - indexed for MEDLINE]
16.

[Blood glucose control and cardiovascular disease in patients with type 2 diabetes. Results of ACCORD, ADVANCE and VA-Diabetes trials].

Radermecker RP, Philips JC, Jandrain B, Paquot N, Scheen AJ.

Rev Med Liege. 2008 Jul-Aug;63(7-8):511-8. French.

PMID:
18771232
[PubMed - indexed for MEDLINE]
17.

Effect of baseline glycemic level on long-term cardiovascular outcomes after coronary revascularization therapy in patients with type 2 diabetes mellitus treated with hypoglycemic agents.

Ehara N, Morimoto T, Furukawa Y, Shizuta S, Taniguchi R, Nakagawa Y, Hoshino K, Saito N, Doi T, Haruna Y, Ozasa N, Imai Y, Teramukai S, Fukushima M, Kita T, Kimura T.

Am J Cardiol. 2010 Apr 1;105(7):960-6. doi: 10.1016/j.amjcard.2009.11.024. Epub 2010 Feb 13.

PMID:
20346313
[PubMed - indexed for MEDLINE]
18.

[Proactive study: secondary cardiovascular prevention with pioglitazione in type 2 diabetic patients].

Scheen AJ, Lefèbvre PJ.

Rev Med Liege. 2005 Nov;60(11):896-901. French.

PMID:
16402538
[PubMed - indexed for MEDLINE]
19.

Effects of intensive glucose lowering in type 2 diabetes.

Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT.

N Engl J Med. 2008 Jun 12;358(24):2545-59. doi: 10.1056/NEJMoa0802743. Epub 2008 Jun 6.

PMID:
18539917
[PubMed - indexed for MEDLINE]
Free Article
20.

Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes.

Chu NV, Kong AP, Kim DD, Armstrong D, Baxi S, Deutsch R, Caulfield M, Mudaliar SR, Reitz R, Henry RR, Reaven PD.

Diabetes Care. 2002 Mar;25(3):542-9. Erratum in: Diabetes Care 2002 May;25(5):947.

PMID:
11874944
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk